Effects of angiotensin II on transient receptor potential melastatin 7 channel function in cardiac fibroblasts

Yanli Zhou1, Xin Yi1, Teng Wang2

  • 1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.

Insights

Angiotensin II (Ang II) influences cardiac fibroblast (CF) behavior by altering transient receptor potential melastatin 7 (TRPM7) channel activity. This study reveals TRPM7

Area of Science:

  • Cardiovascular Physiology
  • Cellular Electrophysiology
  • Fibrosis Research

Background:

  • Cardiac fibroblasts (CFs) play a crucial role in cardiac remodeling and fibrosis.
  • Transient receptor potential melastatin 7 (TRPM7) channels are implicated in cellular processes but their role in Angiotensin II-induced cardiac fibrosis is not fully understood.

Purpose of the Study:

  • To investigate the electrophysiological properties of TRPM7 channels in cardiac fibroblasts.
  • To determine the relationship between Angiotensin II (Ang II) concentration, TRPM7 activity, and collagen production in CFs.
  • To elucidate the role of TRPM7 in Ang II-mediated cardiac fibroblast proliferation and apoptosis.

Main Methods:

  • Primary cardiac fibroblasts (CFs) from Sprague-Dawley rats were cultured.
  • Cells were treated with varying concentrations and time points of Angiotensin II (Ang II).
  • Collagen protein expression and TRPM7 channel currents were measured using established laboratory techniques.

Main Results:

  • 1 nmol/l Ang II was identified as the optimal concentration for inducing fibrosis.
  • TRPM7 and collagen III protein expression, along with TRPM7 currents, peaked at 12 hours of Ang II treatment and subsequently declined.
  • A positive correlation was observed between TRPM7 current levels and collagen production.

Conclusions:

  • TRPM7 channel activity is modulated by Ang II in cardiac fibroblasts.
  • TRPM7 currents are closely linked to collagen synthesis, suggesting a key role in Ang II-induced cardiac fibrosis.
  • Understanding TRPM7 channel function offers potential therapeutic targets for preventing cardiac fibrosis.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K